Profile picture

Professor Li-Ming Gan

Early Clinical Development, Research and Early Development, CVRM, BioPharmaceuti, Gothenburg (Sweden)
Follow
Logo ESC

Contributor content

Inhibition of Factor XI using a GalNAc-siRNA RBD5049: a novel antithrombotic drug with high potency and long duration
Presentation
Inhibition of Factor XI using a GalNAc-siRNA RBD5049: a novel antithrombotic drug with high potency and long duration
Read more
RBD5044 - a novel anti-ApoC3 GalNAc-siRNA drug resulted in sustained and profound reduction of triglycerides in mice and Rhesus monkeys
Presentation
RBD5044 - a novel anti-ApoC3 GalNAc-siRNA drug resulted in sustained and profound reduction of triglycerides in mice and Rhesus monkeys
Read more

ESC 365 is supported by

novartis Explore sponsored resources